Jen Nielsen

Jennifer Nielsen has over 15 years of drug development experience in biotech. She joined CRISPR Therapeutics in early 2018 and is Vice President of in vivo at CRISPR Therapeutics, where she has been identifying in vivo gene editing targets and rapidly advancing in vivo gene editing cardiovascular programs towards the clinic. Previously at CRISPR Therapeutics, she was Executive Director of Program Management, advancing three CRISPR edited CAR T programs into the clinic. Prior to CRISPR Therapeutics, she was Director of Pipeline Strategy and Product Management at Alnylam Pharmaceuticals, where she worked on siRNA products for acute hepatic porphyria and alpha-1 antitrypsin (AAT) deficiency. Prior to Alnylam, she worked at Novartis in Program Leadership in vaccine development. Prior to Novartis, she held various roles across R&D at Shire HGT working on enzyme replacement therapies for lysosomal storage disorders. She has a Bachelor of Science in Biochemistry and Molecular Biology and Master of Science in Biochemistry from the University of New Hampshire.